MSN Labs South Africa

MSN Labs South Africa is committed to advancing healthcare through innovation, quality, and continuous improvement. Backed by MSN’s global capabilities, including 19 API manufacturing plants, 8 finished dosage facilities, and an integrated Research & Development Centre, we deliver high-quality, safe, reliable, and affordable pharmaceutical solutions.

Our focus is to improve patient access, support better health outcomes, and build a stronger healthcare ecosystem through quality medicines, awareness initiatives, robust pharmacovigilance systems, and meaningful partnerships with healthcare professionals and patient communities.

We are strengthening our presence in South Africa by expanding our portfolio, creating commercial synergies, and developing strategic licensing partnerships. Through our research-driven approach and commitment to innovation, we work with stakeholders to bring quality pharmaceutical solutions to patients and build lasting partnerships across the healthcare landscape.

Key Therapeutic Areas

Anti Diabetes
Cardiovascular

Address

The Campus, 57 Sloane Street, Bryanston, Johannesburg, 2191

Medical and Safety Contact

For requests, adverse event reports, technical complaints, or medical information:
PPS Pharmaceuticals (Pty) Ltd,
email: info@ppspharmaceuticals.com.